Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
31 Oct 2008
Transparency Declaration by Capital Research and Management Company (CRMC)
Read More
31 Oct 2008
Transparency Notification of Wellington Management Company LLP
Read More
31 Oct 2008
Fesoterodine approved in the U.S.
Read More
31 Oct 2008
UCB on track
Read More
30 Oct 2008
New Cimzia® study shows rapid reduction of symptoms and progression of rheumatoid arthritis
Read More
29 Oct 2008
UCB's Vimpat® approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults
Read More
25 Sep 2008
UCB withdraws EU marketing authorisation application for lacosamide in diabetic neuropathic pain
Read More
16 Sep 2008
Changes in UCB's Executive Committee
Read More
15 Sep 2008
Keppra XR(TM) approved in the U.S.
Read More
12 Sep 2008
Information Regarding UCB as an Issuer by Virtue of Articles 15 and 18 of the Law of 2 May 2007 on the Disclosure of Major Holdings, as of 1 September 2008
Read More
Pagination
First page
Previous page
‹ Previous
…
Page
86
Page
87
Page
88
Page
89
Current page
90
Page
91
Page
92
Page
93
Page
94
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss